Literature DB >> 11602071

Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk.

K F Clemmer1, A E Binkoski, S M Coval, G Zhao, P M Kris-Etherton.   

Abstract

A large proportion of the United States population requires aggressive low-density lipoprotein (LDL) cholesterol- lowering therapy to meet the new treatment guidelines established by the National Cholesterol Education Program Adult Treatment Panel III. This has further widened the gap between the number of people being treated compared with those who should be treated. Moreover, many people being treated do not meet their LDL cholesterol goal. Diet and healthy lifestyle practices remain the cornerstone of treatment to lower LDL cholesterol. Pharmacologic therapy has assumed an increasingly important role in reaching LDL cholesterol goals. Diet and healthy-lifestyle interventions have been shown to augment the benefits of cholesterol-lowering drugs. Together, this dynamic duo provides the most effective clinical means identified to date for maximally lowering LDL cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602071     DOI: 10.1007/s11883-001-0041-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  42 in total

Review 1.  Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III.

Authors:  K L Radimer; A F Subar; F E Thompson
Journal:  J Am Diet Assoc       Date:  2000-04

2.  Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease.

Authors:  B D Horne; J B Muhlestein; J F Carlquist; T L Bair; T E Madsen; N I Hart; J L Anderson
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

5.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

6.  HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.

Authors:  M J Järvisalo; J O Toikka; T Vasankari; J Mikkola; J S Viikari; J J Hartiala; O T Raitakari
Journal:  Atherosclerosis       Date:  1999-12       Impact factor: 5.162

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.